Free tool
FAERS Monitor: Visionblue
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021670 or its brand name (Visionblue, Trypan Blue). Reports on generic versions are filed under their own applications.
Reports
44
Serious
43
98% of reports
Hospitalization
1
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- toxic anterior segment syndrome24
- blindness21
- corneal oedema10
- product quality issue6
- cerebral infarction3
- endophthalmitis3
- off label use3
- pigmentation disorder3
- thyroid disorder3
- condition aggravated2
- vision blurred2
- corneal decompensation1
- corneal degeneration1
- drug interaction1
- liquid product physical issue1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2014 | 21 |
| 2016 | 6 |
| 2017 | 6 |
| 2018 | 4 |
| 2019 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2025 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,115 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| toxic anterior segment syndromeSignal | 24 | 10762.9 | 8164.4 | 242,178 |
| corneal decompensation | 1 | 2990.6 | 428.1 | 742 |
| corneal oedemaSignal | 10 | 2142.9 | 1240.8 | 19,236 |
| corneal degeneration | 1 | 1985.5 | 284.8 | 493 |
| blindnessSignal | 21 | 246.5 | 180.9 | 4,899 |
| endophthalmitisSignal | 3 | 239.2 | 80.2 | 493 |
| pigmentation disorderSignal | 3 | 232.4 | 77.9 | 479 |
| thyroid disorderSignal | 3 | 93.0 | 31.2 | 189 |
| liquid product physical issue | 1 | 65.5 | 9.4 | 15 |
| cerebral infarctionSignal | 3 | 58.7 | 19.7 | 117 |
| product quality issueSignal | 6 | 21.1 | 10.0 | 96 |
| vision blurred | 2 | 7.0 | 1.8 | 5 |
| condition aggravated | 2 | 3.1 | 0.8 | 1 |
| drug interaction | 1 | 3.0 | 0.4 | 0 |
| off label use | 3 | 1.6 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.